Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis, Covance Sign Commercialization Agreement for Idylla

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis has announced that it has signed a commercialization agreement with Covance, the clinical research organization owned by Laboratory Corporation of America, to offer its Idylla platform and oncology assay menu to Covance's global customer base.

According to Biocartis, the agreement provides for placement of Idylla molecular testing instruments at Covance sites to support customer needs for clinical trials and to validate and implement companion diagnostic applications.

The alliance "is another important step in building an ecosystem around Idylla, this time by deploying our Idylla technology in one of the largest laboratory networks used by the pharmaceutical industry to conduct drug development," Biocartis CEO Herman Verrelst said in a statement. "We believe the fully automated and standardized workflow of our Idylla platform can be of significant value, potentially paving the way for new partnerships with pharmaceutical companies in the context of their oncology treatment developments."

Financial details of the agreement were not disclosed.

Biocartis previously partnered with Bristol-Myers Squibb in March to develop a companion diagnostic for several cancer immunotherapies with an initial focus on colorectal cancer.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.